News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

MYMETICS Corporation' Respiratory Syncytial Virus (RSV) Vaccine Protects From Viral Challenge in Pre-Clinical Study

6/28/2010 10:06:01 AM

EPALINGES, SWITZERLAND--(Marketwire - June 28, 2010) - Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that a pre-clinical study on its Respiratory Syncytial Virus (RSV) vaccine showed protection against a live virus challenge, and a paper reporting these results has now been accepted for publication by the leading scientific journal Vaccine.

In collaboration with the Molecular Virology department of the University of Groningen, the Netherlands, headed by Prof. Wilschut, co-inventor of the vaccine, Mymetics' scientists showed that two consecutive injections of the vaccine at a two-week interval successfully protected mice and cotton rats against a live virus challenge. Vaccination was safe and well tolerated, and all vaccinated animals recovered from the virus challenge, with healthy lungs and having completely cleared the virus. The mice selected (Balb/C strain) have immune systems resembling those of elderly people, who are particularly susceptible to the disease.

The study was run by Mymetics BV (formerly Virosome Biologicals), which was acquired by Mymetics Corporation in 2009. Prior to 2009, Mymetics BV had developed an intranasal influenza vaccine, which successfully cleared Phase I clinical trials and has been licensed to Abbott. The RSV vaccine is based on the proprietary virosome technology platform of Mymetics BV.

Jacques-Francois Martin, CEO of Mymetics Corporation, said, "These significant results further confirm the importance of our acquisition last year, and I am happy to see that the progress of our Dutch team has been acknowledged by this prominent journal. The results also support the broad applicability of our new virosome-based technology to a range of viral diseases."

The paper reporting the results and to be published in Vaccine is titled "Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation".

About Mymetics' Respiratory Syncytial Virus (RSV) vaccine
Respiratory Syncytial Virus (RSV) causes respiratory tract infections in patients of all ages, infecting 64 million people and killing 160'000 worldwide every year. It has a high prevalence in developed countries, affecting those with weak immune systems. It is a major cause of lower respiratory tract infection during infancy, and of life-threatening pulmonary disease among elderly patients. RSV is highly contagious and can be spread through droplets containing the virus when someone coughs or sneezes. Currently, there is no vaccine against RSV. Mymetics' virosome-based RSV vaccine was designed in particular to provide protection for the elderly. It has undergone extensive pre-clinical testing, showing high efficacy, good tolerance and no side effects.

About Mymetics
Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTCBB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are the use of virosomes, lipid-based carriers containing functional viral fusion proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection. Mymetics is led by an international and experienced management team and is supported by a strong Scientific Advisory Board composed of renowned experts. The company has established contacts with world leaders in vaccine development.

Mymetics currently has five vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Herpes Simplex Virus and Malaria. The company's HIV vaccine is entering a new proof-of-concept preclinical trial following unprecedented results in a first study, and is also currently in a Phase I clinical trial in human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been successfully completed, while RSV and HSV vaccine candidates are in the preclinical phase. The Influenza vaccine has been licensed to Solvay Pharmaceuticals (now Abbott). For further information, please visit

Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date the statements were made.

Ronald Kempers
Mymetics Corporation
Tel: +41 21 653 4535

Christophe Lamps
Senior Partner
Dynamics Group
Mobile: + 41 79 476 26 87

US Media:
Michelle Linn
Linnden Communications
508 362 3087

Read at

comments powered by Disqus